The main treatment for stage 4 HER2+ breast cancer is usually systemic therapy — treatment that travels through the body to reach cancer cells wherever they are. The goal is to control growth, relieve symptoms, and improve quality of life. The exact plan depends on where the cancer has spread, prior treatments, biomarkers, and overall health.[1]
Drugs designed to block HER2 signaling or deliver treatment directly to HER2-positive cells. Examples used in metastatic disease include trastuzumab (Herceptin), pertuzumab (Perjeta), tucatinib (Tukysa), and fam-trastuzumab deruxtecan-nxki (Enhertu). Tucatinib is used after at least one other anti-HER2 drug, usually with trastuzumab and capecitabine.[2]
Combined with HER2-targeted drugs to kill rapidly dividing cancer cells. Listed by NCI as one of the main treatments for metastatic breast cancer.[1]
If the tumor is also hormone-receptor-positive (ER+/PR+), endocrine therapy can shrink or slow the cancer.[1]
Used to shrink tumors and relieve symptoms — especially in bone metastases or certain brain lesions.[1]
Not usually the main treatment for metastatic disease, but used in selected cases to remove spread, repair bone, or relieve complications such as fluid buildup.[1]
Not 'giving up.' Includes pain management, emotional support, nutrition, physical therapy, and counseling to improve quality of life alongside disease-directed therapy.[1]
Treatment has changed dramatically in recent years. Trastuzumab deruxtecan (Enhertu) is an antibody-drug conjugate that delivers chemotherapy directly to tumor cells displaying HER2 on their surface. NCI notes that newer studies showed improved outcomes with trastuzumab deruxtecan compared with chemotherapy, expanding its use in metastatic disease.[1]
In December 2025, the FDA approved Enhertu plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, as determined by an FDA-approved test — a sign of how rapidly options continue to evolve.[7]
Active clinical trials are studying personalized treatment plans, tucatinib combinations, and other HER2-directed approaches. Trials may offer access to promising new therapies and help shape future cancer care.[1]
Treatment can extend life and improve it — but it carries costs. Targeted drugs and antibody-drug conjugates may cause nausea, vomiting, diarrhea, fatigue, rash, low blood-cell counts, and infusion reactions. Some newer antibody-drug conjugates can cause serious lung problems in some patients, which is why close monitoring is essential.[2]
Treatment is not only about fighting disease — it's about balancing effectiveness, side effects, and the patient's quality of life.[1]
When asked how treatment affected her quality of life, the answer was simple:
"It kept me alive."
Her regimen — chemotherapy (taxanes), Herceptin for nine years, radiation, and Arimidex — mirrors the multi-front systemic strategy described above. She also chose a hysterectomy because her tumor was ER+/PR+, removing a hormonal fuel source.